A recently released analysis from the Kaiser Family Foundation sheds new light on how rising drug prices are impacting patients' out-of-pocket spending on drugs, as well as the budgets of private and public payers.
A recently released analysis from the Kaiser Family Foundation (KFF) sheds new light on how rising drug prices are impacting patients' out-of-pocket spending on drugs, as well as the budgets of private and public payers.
The analysis drew from data included in the National Health Expenditures Accounts database, the Truven Health Analytics MarketScan Commercial Claims and Encounters Database, and CMS.
According to KFF, the top 50 drug products by spending in 2016 were responsible for a substantial share of total drug pending, yet they accounted for a relatively small share of total prescriptions among large employer plans (39% share of spending vs 8% share of prescriptions), Medicare Part D (43% share of spending vs 15% share of prescriptions), and Medicaid (41% share of spending vs 8% share of prescriptions).
The top 5 drugs products with the highest total spending in 2016 accounted for approximately 10% of total prescription drug spending among large employer plans, Medicare Part D, and Medicaid. Among large employers, Humira ($4.9 billion) and Enbrel ($2.4 billion), both of which have FDA-approved but unlaunched biosimilar options, were responsible for the greatest share of spending.
In Medicare Part D, Harvoni ($4.4 billion) and Revlimid ($2.6 billion) topped the spending charts for 2016, with Lantus Solostar ($2.5 billion) being the drug with the third highest spending under Part D. Medicaid spent the most on Harvoni ($2.2 billion), followed by Humira ($1.3 billion).
Humira and Enbrel also had some of the highest average out-of-pocket spending per user in both large employer plans and Medicare Part D in 2016; in employer plans, patients spent an average of $1123 and $1134 on the 2 branded drugs, respectively. In Part D, they paid $1587 on the pen presentation of Humira and $1610 on Enbrel.
Reflected in the above numbers is the fact that, on average, people covered in Medicare Part D plans spend more out of pocket than those covered through their employer plans. On average, in 2016, Medicare Part D enrollees spend $365 out of pocket on drugs, compared with $132 for those insured through large employers.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.